FK199B
Drugoral
Other names: Zolpidem MR Tablet
NCT Number: NCT00999219
This study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) by polysomnography in patients with insomnia, excluding patients with schizophrenia or manic-depressive psychosis.
Looking for future studies?
Notify Me20 year–65 year
All sexes
Interventional
Phase 3
Chūbu, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral
Other names: Zolpidem MR Tablet
oral
Other names: Myslee
Time frame: 8 hours
Time frame: 8 hours
Time frame: After each night of sleep during the study period
Time frame: After each night of sleep during the study period
Astellas Pharma Inc
Industry
FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07277101
Autism Spectrum Disorder, Autistic Disorder
Shanghai, China
View Trial DetailsNCT04598672
Chronic Disease, Disease Attributes
Oslo, Norway
View Trial DetailsNCT05665764
Brain Diseases, Brain Injuries
Aurora, Colorado, United States
View Trial DetailsNCT03687086
Dyssomnias, Mental Disorders
Los Angeles, California, United States
View Trial Details